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type 2 diabetes inadequately controlled with
metformin: a randomized, double-blind,
placebo-controlled 102-week trial
Clifford J Bailey1*, Jorge L Gross2, Delphine Hennicken3, Nayyar Iqbal4, Traci A Mansfield4 and James F List4Correction
The authors [1] note that the standard errors in Table 3
(Table 1 here) are actually standard deviations. The
reference to standard errors in the footnote has now
been edited accordingly.
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Table 1 Summary of laboratory parameters
PBO + MET
(n = 137)
DAPA 2.5 mg + MET
(n = 137)
DAPA 5 mg + MET
(n = 137)
DAPA 10 mg + MET
(n = 135)
Sodium (mmol/L)
n 72 77 87 93
Baseline 138.9 (2.3) 138.5 (2.9) 138.6 (2.3) 139.1 (2.2)
Change at week 102 −0.04 (2.7) 0.2 (2.8) 0.1 (2.6) 0.1 (2.6)
P vs PBO + MET 0.1434 0.1905 0.3978
Potassium (mmol/L)
n 72 77 87 93
Baseline 4.35 (0.47) 4.34 (0.46) 4.37 (0.39) 4.37 (0.43)
Change at week 102 −0.08 (0.55) −0.01 (0.45) −0.05 (0.35) −0.07 (0.47)
P vs PBO + MET 0.3366 0.4563 0.9918
Serum creatinine (μmol/L)
n 72 77 88 93
Baseline 76.9 (17.9) 78.7 (18.1) 79.6 (19.3) 77.8 (17.8)
Change at week 102 −0.9 (10.3) −1.8 (9.7) −3.5 (12.7) −2.7 (10.6)
P vs PBO + MET 0.9954 0.4720 0.9032
Serum uric acid (μmol/L)a
n 28 35 47 57
Baseline 314 (79) 322 (80) 323 (88) 323 (80)
Change at week 102 −1.78 (54.13) −55.9 (50.32) −46.4 (64.36) −52.9 (64.36)
P vs PBO + MET 0.0054 0.0013 0.0002
Blood urea nitrogen (mmol/L)
n 72 77 88 93
Baseline 5.33 (1.55) 5.51 (1.41) 5.65 (1.81) 5.34 (1.41)
Change at week 102 0.56 (1.24) 0.70 (1.54) 0.42 (1.87) 0.73 (1.44)
P vs PBO + MET 0.2299 0.4169 0.0845
Haematocrit (%)
n 71 78 87 93
Baseline 42.61 (3.90) 42.38 (3.99) 42.15 (3.59) 42.88 (3.95)
Change at week 102 −1.43 (3.29) 0.84 (2.53) 1.35 (2.48) 1.54 (2.78)
P vs PBO + MET <0.0001 <0.0001 <0.0001
Haemoglobin (g/L)
n 71 78 87 94
Baseline 142.8 (13.45) 142.5 (14.25) 141.6 (12.19) 143.6 (13.10)
Change at week 102 −4.9 (10.14) 1.5 (7.73) 3.1 (8.40) 4.1 (8.84)
P vs PBO + MET <0.0001 <0.0001 <0.0001
Systolic blood pressure (mm Hg)
n 72 78 88 94
Baseline 128 (15) 127 (14) 127 (14) 126 (16)
Change at week 102 1.5 (13.7) 0.7 (16.1) −1.1 (13.2) −0.3 (15.0)
P vs PBO + MET 0.1111 0.0136 0.0067
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Table 1 Summary of laboratory parameters (Continued)
Diastolic blood pressure (mm Hg)
n 72 78 88 94
Baseline 81 (9) 80 (9) 81 (9) 79 (10)
Change at Week 102 −1.0 (7.9) −0.1 (8.1) −1.5 (8.1) −1.2 (10.1)
P vs PBO + MET 0.6605 0.2140 0.1075
Data are means (SD) at baseline or mean changes (SD) from baseline at week 102 including data after rescue unless noted. n is the number of treated patients
with non-missing baseline and Week 102 values for the specific test. aExcluding data after rescue. Abbreviations: SD standard deviation, SE standard error, PBO
placebo, MET metformin, DAPA dapagliflozin.
Bailey et al. BMC Medicine 2013, 11:193 Page 3 of 3
http://www.biomedcentral.com/1741-7015/11/193Author details
1Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.
2Endocrine Division, Universidade Federal do Rio Grande do Sul, Avenida
Paulo Gama 110-Reitoria, Porto Alegre 90040-060, Brazil. 3Global Biometric
Services, Bristol-Myers Squibb, Parc de l’Alliance, Avenue de Finlande 4,
Braine I’Alleud B-1420, Belgium. 4Global Clinical Research, Bristol-Myers
Squibb, Route 206 & Province Line Road, Princeton, NJ 08543, USA.
Received: 20 August 2013 Accepted: 20 August 2013
Published: 2 September 2013
Reference
1. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF: Dapagliflozin
add-on to metformin in type 2 diabetes inadequately controlled with
metformin: a randomized, double-blind, placebo-controlled 102-week
trial. BMC Medicine 2013, 11:43.
doi:10.1186/1741-7015-11-193
Cite this article as: Bailey et al.: Correction: Dapagliflozin add-on to
metformin in type 2 diabetes inadequately controlled with metformin: a
randomized, double-blind, placebo-controlled 102-week trial. BMC
Medicine 2013 11:193.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
